A randomized clinical trial suggests that psilocybin for cocaine use disorder, delivered alongside structured psychotherapy, may help people reduce or stop cocaine use. The findings introduce a potential new direction for a condition that currently has no approved pharmacological treatment.
A Persistent Gap In Addiction Treatment
Cocaine use disorder remains difficult to treat. Behavioral interventions, including contingency management and cognitive behavioral therapy, can improve outcomes, but access and sustained engagement remain inconsistent.
Unlike opioid or alcohol use disorders, cocaine use disorder has no medication specifically approved by the US Food and Drug Administration. Numerous pharmacological candidates have been studied, yet none has established sufficient efficacy for routine treatment.
Testing Psilocybin For Cocaine Use Disorder
Researchers at the University of Alabama at Birmingham enrolled 40 adults who wanted to stop using cocaine. Participants were randomly assigned to receive either a single oral dose of psilocybin or an active placebo containing diphenhydramine.
Everyone received the same manualized psychotherapy program. It combined a client-centered approach with cognitive behavioral treatment through preparation sessions, an all-day medication session, and weekly integration sessions.
This design allowed investigators to examine whether psilocybin produced benefits beyond those associated with psychotherapy, clinical attention, and participation in a structured treatment program.
A Rigorous Trial With Extended Follow-Up
The quadruple-blind trial masked participants, therapists, outcome assessors, and independent statisticians to treatment assignments. Cocaine use was measured through timeline follow-back interviews and checked with urine testing.
Researchers followed participants for 180 days after treatment. They assessed the percentage of cocaine-abstinent days, complete abstinence, and the time before a first cocaine lapse.
The study also included participants frequently underrepresented in psychedelic research. Most were Black, and nearly two-thirds reported annual incomes of $20,000 or less.
Abstinent Days Increased After Treatment
Participants who received psilocybin reported a significantly higher percentage of cocaine-abstinent days than those who received placebo. The adjusted difference between groups was approximately 29 percentage points across the post-treatment period.
Six of the 20 psilocybin recipients maintained complete abstinence through day 180. None of the 20 placebo recipients achieved complete abstinence over the same period.
Psilocybin recipients also had a lower risk of cocaine lapse. The hazard ratio was 0.28, indicating a substantially reduced likelihood of returning to cocaine use during follow-up.
Psychotherapy Remains Central To The Model
These results do not establish psilocybin as a stand-alone treatment. The intervention included extensive preparation, supervised dosing, and post-session integration within a structured therapeutic relationship.
Psilocybin primarily activates serotonin 2A receptors and can temporarily alter perception, emotional processing, and patterns of thought. In an addiction treatment setting, that experience may help some individuals reconsider established behaviors or engage more deeply with therapeutic goals.
The trial was not designed to determine precisely which psychological or neurobiological mechanisms produced the observed improvements.
A Notable But Preliminary Signal
Several features strengthen the findings, including randomization, an active placebo, urine verification, extended follow-up, and intention-to-treat analysis. The inclusion of a socioeconomically vulnerable and predominantly Black study population also expands representation within psychedelic research.
Important limitations remain. The sample included only 40 participants, estimates for complete abstinence had wide confidence intervals, and psilocybin’s noticeable effects made successful blinding difficult. The lead investigator also served as the primary therapist, introducing a possible source of allegiance bias.
Adverse events were more common with psilocybin, but no serious treatment-related events occurred. Reported effects were generally expected and resolved without lasting consequences.
A Path Toward Larger Confirmatory Trials
The study provides an encouraging signal that psilocybin-assisted psychotherapy could eventually expand treatment options for cocaine use disorder. It does not yet support routine clinical use.
Larger multisite trials will need to replicate the findings, clarify safety across broader patient populations, evaluate treatment durability, and determine how psychotherapy contributes to outcomes. Until then, psilocybin for cocaine use disorder should be viewed as a promising investigational approach rather than an established therapy.
Citations
Explore more at https://www.interventionalpsychiatry.org/
